ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

OLMA vs IMMX // OPTIONS IMPLIED MOVE & PUT/CALL SKEW

Olema Pharmaceuticals Inc. (NASDAQ) VS. Immix Biopharma Inc. (NASDAQ) • 15-METRIC TALLY: OLMA 2 — IMMX 2
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (OLMA VS. IMMX) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC OLMA IMMX SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -32.80% -35.00% +2.20 OLMA /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield -22.88% -3.73% -19.15 IMMX /fcf-yield <GO>
Operating Margin — — — TIE /operating-margins <GO>
Net Profit Margin — — — TIE /net-margins <GO>
Revenue Growth (YoY) — — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 2/9 2/9 0.00 TIE /piotroski-score <GO>
Options Implied Move & Put/Call Skew ACTIVE — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 41.3 32.8 +8.50 OLMA /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $612.5M $636.7M -$24.2M IMMX /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR OLMA REV IMMX REV OLMA GROSS % IMMX GROSS % OLMA FCF IMMX FCF
FY 2025 $500.4M $83.9M — — -$146.7M -$24.7M
FY 2024 $398.3M $63.5M — — -$104.5M -$15.8M
FY 2023 $293.9M $45.2M — — -$83.7M -$11.4M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
OLMA // BETA —
IMMX // BETA —